What is the maximum recommended dose of midodrine (alpha-1 adrenergic receptor agonist) for treating orthostatic hypotension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Recommended Dose of Midodrine for Orthostatic Hypotension

The maximum recommended dose of midodrine for treating orthostatic hypotension is 10 mg three times daily, with a total daily maximum of 30 mg. 1

Dosing Guidelines

Standard Dosing

  • Starting dose: 10 mg three times daily 1
  • Dosing schedule: Approximately 4-hour intervals during daytime hours when upright activity is needed 1
    • Suggested timing: morning (upon arising), midday, and late afternoon (not later than 6 PM)
  • Alternative interval: Can be given at 3-hour intervals if needed to control symptoms, but not more frequently 1

Dose Adjustments

  • Maximum single dose: Single doses as high as 20 mg have been given to patients, but this causes severe and persistent systolic supine hypertension in about 45% of patients 1
  • Maximum daily dose: Total daily doses greater than 30 mg have been tolerated by some patients, but their safety and usefulness have not been systematically established 1
  • Renal impairment: For patients with abnormal renal function, initiate treatment using 2.5 mg doses and titrate cautiously 1

Administration Considerations

Timing of Administration

  • Last dose timing: Should not be given after the evening meal or less than 4 hours before bedtime to reduce the risk of supine hypertension during sleep 1
  • Daytime use only: Dosing should take place during daytime hours when the patient needs to be upright for daily activities 1

Monitoring

  • Blood pressure monitoring: Supine and standing blood pressure should be regularly monitored 1
  • Discontinuation criteria: Administration should be stopped if supine blood pressure increases excessively 1
  • Efficacy assessment: Should be continued only in patients who demonstrate symptomatic improvement during initial treatment 1

Clinical Evidence for Efficacy

  • A double-blind, dose-response study found that 10 mg of midodrine increased standing systolic blood pressure by approximately 30 mmHg at 1 hour, with effects partially sustained for 2 hours 1, 2
  • The 10 mg dose demonstrated significant improvement in orthostatic symptoms including dizziness, lightheadedness, weakness, and fatigue compared to placebo 3
  • In patients with neurogenic orthostatic hypotension, midodrine at 10 mg three times daily resulted in a 27% (22 mmHg) increase in standing systolic blood pressure 4

Special Considerations

Hepatorenal Syndrome

  • In patients with hepatorenal syndrome, midodrine has been used in combination with octreotide and albumin, with midodrine titrated up to a maximum of 12.5 mg orally three times per day 5

Potential Side Effects

  • Common side effects: Piloerection, scalp itching/tingling, nausea, urinary urgency, headache 6
  • Major concern: Supine hypertension (occurs in up to 25% of patients) 6
  • Contraindications: Should not be used in patients with acute kidney injury with serum creatinine ≥5 mg/dL 6

Practical Application

  1. Start with 10 mg three times daily during daytime hours
  2. Space doses at least 3-4 hours apart
  3. Administer last dose no later than 6 PM
  4. Monitor both supine and standing blood pressure regularly
  5. Discontinue if excessive supine hypertension develops
  6. For patients with renal impairment, start at 2.5 mg and titrate cautiously
  7. Do not exceed 30 mg total daily dose

Remember that midodrine is a prodrug that forms the active metabolite desglymidodrine, which has a half-life of 3-4 hours, explaining the need for multiple daily dosing 1.

References

Research

Midodrine in neurogenic orthostatic hypotension. A new treatment.

International angiology : a journal of the International Union of Angiology, 1993

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Atrial Fibrillation and Midodrine Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.